Usefulness of transbronchial lung cryobiopsy when choosing treatment for chronic fibrosing interstitial lung disease: Descriptive research

Author:

Takatsuka Makiko1,Yamakawa Hideaki1,Takemura Tamiko2,Sato Shintaro1,Ohta Hiroki1,Kusano Kenji1,Oba Tomohiro1,Kawabe Rie1,Akasaka Keiichi1,Sasaki Hiroki1,Amano Masako1,Araya Jun3,Matsushima Hidekazu1

Affiliation:

1. Saitama Red Cross Hospital

2. Kanagawa Cardiovascular and Respiratory Center

3. Tokyo Jikei University Hospital

Abstract

Abstract Background: Although transbronchial lung cryobiopsy (TBLC) is widely used in diagnostic algorithms for various interstitial lung diseases (ILD), its real-world utility in the therapeutic decision-making strategy for ILD patients remains unclear. Methods: We analyzed medical records of 40 consecutive patients with idiopathic or fibrotic hypersensitivity pneumonitis who underwent TBLC. A TBLC-based usual interstitial pneumonia (UIP) score was used to assess three morphologic descriptors: i) patchy fibrosis, ⅱ) fibroblastic foci, and ⅲ) honeycombing. Results: In our 40 patients with ILD, the most frequent radiological feature was indeterminate for UIP (45.0%). Final diagnosis included idiopathic pulmonary fibrosis (22.5%), fibrotic nonspecific interstitial pneumonia (5.0%), fibrotic hypersensitivity pneumonitis (35.0%), and unclassifiable ILD (37.5%). Linear mixed-effects analysis showed that declines in the slopes of %FVC and %DLCO in patients with TBLC-based UIP ‘Score ≥2’ were significantly steeper than those of patients with ‘Score ≤1’. During follow-up of patients with ‘Score ≥2’ (n = 24), more than half of them received combination therapy (i.e., anti-inflammatory and anti-fibrotic agents). Moreover, in the groups receiving an anti-fibrotic agent, many patients received anti-fibrotic agent administration within 6 months after the TBLC procedure. Among the groups with combination therapy, most patients received an anti-fibrotic agent within 6 months of the multi-disciplinary discussion-based diagnosis. Conclusions: TBLC-based UIP score ≥2 indicated the increased possibility of a progressive fibrosis course that may prove helpful in predicting progressive pulmonary fibrosis/progressive fibrosing ILD even if disease is temporarily stabilized due to anti-inflammatory agents. Patients may benefit from early introduction of anti-fibrotic agents by treating clinicians.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3